The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
复制标题
DOI：
10.1016/s1074-7613(00)80066-7
复制
发表时间：
1999-06-01
期刊：
影响因子：
32.4
通讯作者：
Nadler, LM
中科院分区：
文献类型：
--
作者：
Vonderheide, RH;Hahn, WC;Nadler, LM
在某些人类恶性肿瘤中发现肿瘤相关抗原（TAA）促使人们重新努力开发抗原特异性癌症免疫疗法。然而，迄今为止描述的大多数 TAA 在一种或几种肿瘤类型中表达，并且在患有这些类型肿瘤的患者中，TAA 表达并不普遍。在这里，我们将端粒酶催化亚基 (hTERT) 描述为一种广泛表达的 TAA，能够触发抗肿瘤细胞毒性 T 淋巴细胞 (CTL) 反应。超过 85% 的人类癌症表现出很强的端粒酶活性，但正常成人组织（除了少数例外）却没有。在人类系统中，CD8(+) CTL 对 hTERT 肽具有特异性，且仅限于 MHC HLA-A2，可裂解来自多种组织学的 hTERT(+) 肿瘤。这些发现将 hTERT 确定为抗癌免疫治疗策略的潜在重要且广泛适用的靶点。
The discovery of tumor-associated antigens (TAA) in certain human malignancies has prompted renewed efforts to develop antigen-specific immunotherapy of cancer. However, most TAA described thus far are expressed in one or a few tumor types, and, among patients with these types of tumors, TAA expression is not universal. Here, we characterize the telomerase catalytic subunit (hTERT) as a widely expressed TAA capable of triggering antitumor cytotoxic T lymphocyte (CTL) responses. More than 85% of human cancers exhibit strong telomerase activity, but normal adult tissues, with few exceptions, do not. In a human system, CD8(+) CTL specific for an hTERT peptide and restricted to MHC HLA-A2 lysed hTERT(+) tumors from multiple histologies. These findings identify hTERT as a potentially important and widely applicable target for anticancer immunotherapeutic strategies.